In preclinical models of human breast cancer, Angiolix had a significant anticancer effect in vivo; this effect was enhanced when Angiolix was given in combination with conventional chemotherapy for breast cancer. The studies were conducted at Imperial College London.
Access is continuing to conduct preclinical studies at Imperial College London to more fully define the safety and efficacy profile of Angiolix.
Jeffrey Davis, president and CEO of Access Pharmaceuticals, said: “We are delighted with these results which demonstrate the substantial anticancer effect of Angiolix, which we feel is comparable to Avastin yet achieved through a different and potentially complementary mechanism of action. As stated previously, Access is actively seeking potential partners for the further clinical development of Angiolix.”